Publications by authors named "A Buge"

Claim this Profile
I
Is it possible to predict atherosclerosis in the ascending aorta by the patient's lipid panel?
İsmail Haberal, Mehmet Ali Yesiltas, Ahmet Ozan Koyuncu, Sebnem Batur, Sadiye Deniz Ozsoy, Aysim Buge

Arch Med Sci Atheroscler Dis· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[N1-hetarylcarbonyl substituted amidrazones and 3,5-disubstituted 1,2,4-triazoles as potential antimyocobacterial agents].
D Ranft, G Lehwark-Yvetot, K J Schaper, A Büge

Pharmazie· March 2001

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N1-Hetaryl substituted pyridine- and pyrazinecarboxamidrazones with antimycobacterial activity.
D Ranft, G Lehwark-Yvetot, K J Schaper, A Büge

Arch Pharm (Weinheim)· June 1997

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Lipoxygenase inhibitors. 3. Synthesis of tetrahydrobenzazepinone phenylhydrazones].
A Büge, C Locke, T Köhler, P Nuhn

Arch Pharm (Weinheim)· February 1994

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Synthesis of lipoxygenase inhibitors. 1. Synthesis of open-ring amidrazones].
P Nuhn, A Büge, P Harenberg, H Lettau, K Moschner

Pharmazie· May 1993

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis